Coldstream Capital Management’s AbbVie ABBV Stock Holding History

Coldstream Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-400	Closed	-$23K	–	196
2014 Q2	$23K	Buy	+400	New	+$21K	0.01%	209

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Coldstream Capital Management's ABBV Position: Q2 2026 in Review

Coldstream Capital Management reduced its AbbVie (ABBV) stake by 1.4% in Q2 2026, selling an estimated $217K and leaving 73,209 shares worth $18.4M. The position accounts for 0.23% of the portfolio, ranked #73.

Coldstream Capital Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Coldstream Capital Management held 73,209 shares of AbbVie worth $18.4M as of Q2 2026.
Coldstream Capital Management sold 1,008 AbbVie shares in Q2 2026, an estimated $217K.
AbbVie made up 0.23% of Coldstream Capital Management's portfolio in Q2 2026, its #73 holding.
Coldstream Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.